| Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes K Yamaguchi, M Mandai, T Oura, N Matsumura, J Hamanishi, T Baba, ... Oncogene 29 (12), 1741-1752, 2010 | 212 | 2010 |
| Single amino acid residue as a functional determinant of rod and cone visual pigments H Imai, D Kojima, T Oura, S Tachibanaki, A Terakita, Y Shichida Proceedings of the National Academy of Sciences 94 (6), 2322-2326, 1997 | 168 | 1997 |
| Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm H Negoro, A Kanematsu, M Doi, SO Suadicani, M Matsuo, M Imamura, ... Nature communications 3 (1), 809, 2012 | 136 | 2012 |
| Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised … N Inagaki, M Takeuchi, T Oura, T Imaoka, Y Seino The Lancet Diabetes & Endocrinology 10 (9), 623-633, 2022 | 107 | 2022 |
| Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug (s): results … N Inagaki, Y Atsumi, T Oura, H Saito, T Imaoka Clinical therapeutics 34 (9), 1892-1908. e1, 2012 | 97 | 2012 |
| Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in J apanese patients with type 2 … E Araki, N Inagaki, Y Tanizawa, T Oura, M Takeuchi, T Imaoka Diabetes, Obesity and Metabolism 17 (10), 994-1002, 2015 | 87 | 2015 |
| The activated transforming growth factor‐beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer S Yamamura, N Matsumura, M Mandai, Z Huang, T Oura, T Baba, ... International Journal of Cancer 130 (1), 20-28, 2012 | 81 | 2012 |
| Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling N Matsumura, M Mandai, T Okamoto, K Yamaguchi, S Yamamura, T Oura, ... Cancer science 101 (12), 2658-2663, 2010 | 43 | 2010 |
| A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes K Furihata, H Mimura, S Urva, T Oura, K Ohwaki, T Imaoka Diabetes, Obesity and Metabolism 24 (2), 239-246, 2022 | 41 | 2022 |
| Isomer-specific interaction of the retinal chromophore with threonine-118 in rhodopsin T Nagata, T Oura, A Terakita, H Kandori, Y Shichida The Journal of Physical Chemistry A 106 (10), 1969-1975, 2002 | 39 | 2002 |
| A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial M Emoto, Y Terauchi, A Ozeki, T Oura, M Takeuchi, T Imaoka Endocrine Journal 62 (12), 1101-1114, 2015 | 36 | 2015 |
| Molecular properties of chimerical mutants of gecko blue and bovine rhodopsin D Kojima, T Oura, O Hisatomi, F Tokunaga, Y Fukada, T Yoshizawa, ... Biochemistry 35 (8), 2625-2629, 1996 | 35 | 1996 |
| Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes Y Onishi, T Oura, H Nishiyama, S Ohyama, M Takeuchi, N Iwamoto Endocrine Journal 63 (3), 263-273, 2016 | 27 | 2016 |
| Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan Y Onishi, T Oura, A Matsui, J Matsuura, N Iwamoto Endocrine journal 64 (5), 553-560, 2017 | 26 | 2017 |
| Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 … M Shiramoto, R Nasu, T Oura, M Imori, K Ohwaki Journal of Diabetes Investigation 11 (3), 672-680, 2020 | 22 | 2020 |
| Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1 T Okamoto, N Matsumura, M Mandai, T Oura, Y Yamanishi, A Horiuchi, ... Modern Pathology 24 (2), 267-276, 2011 | 22 | 2011 |
| Effect of once-weekly dulaglutide on glucose levels in Japanese patients with type 2 diabetes: findings from a phase 4, randomized controlled trial M Inoue, M Shiramoto, T Oura, R Nasu, M Nakano, M Takeuchi Diabetes therapy 10, 1019-1027, 2019 | 14 | 2019 |
| Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono substudy) D Yabe, D Kawamori, Y Seino, T Oura, M Takeuchi Diabetes, Obesity and Metabolism 25 (2), 398-406, 2023 | 13 | 2023 |
| 1024-P: effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM K Ohwaki, K Furihata, H Mimura, T Oura, T Imaoka Diabetes 68 (Supplement_1), 2019 | 12 | 2019 |
| Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 … S Kaneko, T Oura, A Matsui, T Shingaki, M Takeuchi Endocrine journal 64 (12), 1165-1172, 2017 | 12 | 2017 |
